

**PBPS Journal Watch**

**April- May 2021**

**1. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification. A Validation Study From a Single-Institution Retrospective Analysis.**

Hayes AR, Furnace M, Shah R, et al. *Pancreas*. 2021;50(4):516-523.

<https://pubmed.ncbi.nlm.nih.gov/33939663/>

**2. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.**

Yugawa K, Itoh S, Yoshizumi T, et al. *Mod Pathol*. 2021 Apr;34(4):798-807.

<https://pubmed.ncbi.nlm.nih.gov/33077921/>

**3. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.**

Rasmussen LG, Verbeke CS, Sørensen MD, et al. *Pancreatology* 2021;21(3):530-543.

<https://pubmed.ncbi.nlm.nih.gov/33637450.>

**4. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.**

Kim SH, Hwang HK, Lee WJ, Kang CM. *Pancreatology* 2021;21(3):544-549.

<https://pubmed.ncbi.nlm.nih.gov/33612442.>

**5. The impact of different metastatic patterns on survival in patients with pancreatic cancer.**

He C, Huang X, Zhang Y, Lin X, Li S. *Pancreatology*. 2021;21(3):556-563.

<https://pubmed.ncbi.nlm.nih.gov/33518454.>

**6. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.**

Murakami Y, Nakagawa N, Kondo N, et al. *Pancreatology* 2021;21(3):564-572.

<https://pubmed.ncbi.nlm.nih.gov/33526385>.

**7. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential.**

Nakamura K, Sho M, Akahori T, et al. Pancreatology 2021;21(3):573-580.

<https://pubmed.ncbi.nlm.nih.gov/33541781>.

**8. Evaluation of the significance of adjuvant chemotherapy in patients with stage I A pancreatic ductal adenocarcinoma.**

Izumo W, Higuchi R, Furukawa T, et al. Pancreatology 2021;21(3):581-588.

<https://pubmed.ncbi.nlm.nih.gov/33579600>.

**9. Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements.**

Dbouk M, Brewer Gutierrez OI, et al. Pancreatology 2021;21(3):613-621.

<https://pubmed.ncbi.nlm.nih.gov/33593706>.

**10. Paraganglia of the Gallbladder: An Underrecognized Incidental Finding and Potential Diagnostic Pitfall.**

Ramlal B, Voytek T, Ligato S. Arch Pathol Lab Med 2021;145(4):437-440.

<https://pubmed.ncbi.nlm.nih.gov/32886744>.

**11. The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary Cancer: A Review and Update.**

Liao X, Zhang D. Arch Pathol Lab Med 2021;145(5):543-553.

<https://pubmed.ncbi.nlm.nih.gov/32223559>.

**12. 500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance.**

Zureikat AH, Beane JD, Zenati MS, et al. Ann Surg 2021;273(5):966-972.

<https://pubmed.ncbi.nlm.nih.gov/31851003>

**13. Reappraisal of a 2-Cm Cut-off Size for the Management of Cystic Pancreatic Neuroendocrine Neoplasms: A Multicenter International Study.**

Maggino L, Schmidt A, Käding A, et al; on the behalf on the Pancreas 2000 research group. Ann Surg 2021;273(5):973-981.

<https://pubmed.ncbi.nlm.nih.gov/31348038>.

**14. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study.**

Karamitopoulou E, Esposito I, Zlobec I, et al. Virchows Arch. 2021 Apr;478(4):719-726.

<https://pubmed.ncbi.nlm.nih.gov/33330964/>

**15. T2 gallbladder cancer shows substantial survival variation between continents and this is not due to histopathologic criteria or pathologic sampling differences.**

DeSimone MS, Goodman M, Pehlivanoglu B, et al. Virchows Arch. 2021 May;478(5):875-884.

<https://pubmed.ncbi.nlm.nih.gov/33411027/>

**16. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.**

Gout J, Perkhofer L, Morawe M, et al. Gut. 2021 Apr;70(4):743-760.

<https://pubmed.ncbi.nlm.nih.gov/32873698/>

**17. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions.**

Fujikura K, Hosoda W, Felsenstein M, et al. Gut. 2021 May;70(5):928-939.

<https://pubmed.ncbi.nlm.nih.gov/33028669/>

**18. Evaluation and Pathologic Classification of Choledochal Cysts: Clinicopathologic Analysis of 84 Cases From the West.**

Aydin Mericöz, Cisel; Hacıhasanoglu, Ezgi; Muraki, Takashi; et al. Am J Surg Pathol 2021, 45(5):627-637.

<https://pubmed.ncbi.nlm.nih.gov/33481384>

**19. Rosai-Dorfman disease of the pancreas: Cytologic analysis of three cases presenting as pancreatic masses.**

Roe CJ, Tracht J, Madrigal E, et al. Diagn Cytopathol 2021, 49 (4): E181-E186.

<https://pubmed.ncbi.nlm.nih.gov/33058558>

**20. Reappraisal of pathological features of Intraductal papillary neoplasm of bile duct with respect to the type 1 and 2 subclassifications.**

Nakanuma Y, Uesaka K, Okamura Y, et al. Hum Pathol. 2021 May; 111:21-35.

<https://pubmed.ncbi.nlm.nih.gov/33508254/>

**21. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy.**

Das KK, Brown JW, Fernandez del-Castillo C, et al. Hum Pathol. 2021 May; 111:36-44.

<https://pubmed.ncbi.nlm.nih.gov/33524436/>

**22. Increasing tumor budding in cholangiocarcinoma is associated with decreased disease-specific survival.**

Agostini-Vulaj D, M M Gates J, Bratton LE, et al. Hum Pathol. 2021 May; 111:75-83.

<https://pubmed.ncbi.nlm.nih.gov/33727168/>

**Journal Watch Team (in alphabetical order):**

1. Dr. Daniela Allende (Editor), Cleveland Clinic.
2. Dr. Serdar Balci, Memorial Hospitals Group Istanbul Turkey.
3. Dr. Deyali Chatterjee, The University of Texas MD Anderson Cancer Center.
4. Dr. Deepti Dhall, University of Alabama at Birmingham.
5. Dr. Eva Karamitopoulou, Universität Bern Institut für Pathologie.
6. Dr. Claudio Luchini, University of Verona.
7. Dr. Ilke Nalbantoglu, Yale University.

8. Dr. Hanlin Wang, UCLA Medical Center.

**List of journals reviewed:**

1. AJSP
2. Pancreatology
3. Gastroenterology
4. Hepatology
5. Modern Path
6. Histopathology
7. Journal of Molecular Diagnostics
8. Virchows Archives
9. Human Pathology
10. Am J Gastroenterol
11. Pancreas
12. Clin Gastroenterol and Hepatol
13. Gut
14. American J Clin Pathol
15. Archives of Pathol and Lab Med
16. Seminars in Diagnostic Pathology
17. Cancer Cytopathology
18. Journal of American Society of Cytopathology
19. Diagnostic Cytopathology
20. Annals of Surgical Oncology
21. Annals of Surgery
22. Endocrine Pathology
23. Cancer
24. International Journal of Surgical Pathology
25. Generic organ specific searches

